Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW BRUNSWICK, N.J., Sept. 28, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced Katalin Karikó, Ph.D.

Johnson & Johnson Celebrates COVID-19 Vaccine Science Superheroes

Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), announced new data from the Phase 3 UNIVERSE study comparing Xarelto (rivaroxaban). The data showed that Xarelto in an oral suspension formulation, compared to aspirin, was associated with fewer blood clots than aspirin in patients ages 2-8 who have had the Fontan procedure.

J&J's Xarelto Tops Aspirin With Fewer Blood Clots In Pediatric Patients

Apple

Abbott Labs

Amplify Lithium & Battery Technology ETF

Blackrock Inc

Carrier Global

Colgate-Palmolive

CVS Health

Chevron

Invesco DB Commodity Index Tracking Fund

General Electric

iShares Core S&P 500 ETF

Coca-Cola

Lowe's

Medtronic

Microsoft

NIKE

ProShares S&P 500 Dividend Aristocrats ETF

Otis Worldwide

PepsiCo

Procter & Gamble

QUALCOMM

Raytheon Technologies

Texas Instruments

Vanguard Dividend Appreciation ETF

Walgreens

Walmart

Exxon Mobil

The Dividend Aristocrats have historically beat the market with less volatility. Can you improve your odds by paying attention to certain metrics such as quality or safety?

Going One Better Than The Dividend Aristocrats

Pfizer

Target

These stocks are Dividend Kings for a reason, and they look really well poised to grow manifold in the coming years.

5 Top Dividend Kings to Buy Now and Hold Forever

Brookfield Renewable Partners

The legendary investor's rules are simple yet difficult to pull off. These stocks should make following them easier.

3 Stocks to Buy to Follow Warren Buffett's 2 Rules for Investing

Johnson & Johnson vaccine recipients feel left out of the conversation about booster shots. But second shots are likely.

J&J recipients are feeling neglected as booster campaigns begin, but second shots are likely coming soon

The company trades at 17x earnings, lower than the 19x historic average.

Johnson & Johnson Can Still Deliver

J&J stock has fallen 9% over the past month from its recent highs. In doing so, it has now headed back to a fair price right in line with its historical dividend yield.

Ignore Recent Jitters, Johnson & Johnson Is A Buy

The positive data update has put the spotlight on a number of ETFs that could benefit from their high exposure to Johnson & Johnson.

J&J ETFs to Gain on Upbeat COVID-19 Vaccine Data

Electronic Arts

Estee Lauder

Icahn Enterprises

Logitech

National Health Investors

Nucor

V.F.

Voya Financial

Brookfield Infrastructure

Despite hot markets there are plenty of stocks to buy whose relative strength index (RSI) indicates they are oversold. Here are 10 options.

10 Oversold Stocks to Buy for the Final Quarter

AbbVie

Gilead Sciences

These stocks should be less volatile than many of the alternatives.

3 Relatively Safe Pharma Stocks You Can Buy Right Now

J&J's (JNJ) data showed that a booster dose of its vaccine generated 94% efficacy against mild-to-severe COVID-19 in the United States. The data also confirmed that even one dose offers strong and long-lasting protection.

J&J's (JNJ) New Data Shows COVID-19 Booster Ups Protection

Moderna

Housing Starts came in at 1.62 million, higher than the 1.55 million estimate, which happened to be the headline number for July.

Housing Data Better than Expected on Growth in Northeast

Fed's FOMC Meeting in Focus

With recent updates from Pfizer Inc. ( PFE , Financial) and BioNTech SE ( BNTX , Financial) regarding the effectiveness of their Covid-19 vaccine among children ages 5 to 11 and Johnson & Johnson's ( JNJ , Financial) booster shot announcement, consumers and investors alike are continuing to carefully watch the health care space.

2 Outperforming Biotech Stocks to Examine on Covid-19 Vaccine Updates

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Advocates from AIDS Healthcare Foundation (AHF) and its partner organizations will hold a demonstration at the global headquarters of Johnson & Johnson (J&J), maker of a key single-shot COVID-19 vaccine, over the drug company's ‘pandemic profiteering.' The protest, part of the AHF-led ‘Vaccinate Our World' (VOW) campaign, will be held in New Brunswick, New Jersey on Wednesday, Sept. 22 at 12 noon ET. AHF's J&J protest will also take place the sa

Activists to Protest J&J's ‘Pandemic Profiteering' at New Jersey HQ Sept. 22

Johnson & Johnson became the latest COVID-19 vaccine maker to offer an update on booster doses Tuesday, when it said data from a Phase 3 trial and the real world found protection against hospitalization and death is greatly improved by a booster jab of its one-shot vaccine.

Coronavirus Update: J&J says booster greatly improves COVID-19 vaccine efficacy as experts await FDA decision

Visa

When setting out to construct a portfolio, investors should make sure to add high quality names to their shopping list, especially if they expect their investments to provide income in retirement.

3 Highly Profitable Low-Risk Stocks to Own

News for Johnson & Johnson Stock (JNJ)